Sulbutiamine shows promising results in reducing fatigue in patients with multiple sclerosis


      • Fatigue is the most frequent and often debilitating symptom for patients with MS.
      • There are no available effective drugs for fatigue associated with MS.
      • Sulbutiamine increases the levels of thiamine and its phosphate esters in the brain.
      • In the current study sulbutiamine intake reduced fatigue symptoms in patients with MS.
      • This is the first study to show a positive effect of sulbutiamine on fatigue in MS.



      Fatigue is the most frequent and often debilitating symptom for patients with multiple sclerosis (MS). There are no available effective therapies for fatigue associated with MS, and it is unclear whether a successful therapy of MS leads to clinical improvement. Sulbutiamine is a lipophilic compound that crosses the blood–brain barrier more readily than thiamine and increases the levels of thiamine and thiamine phosphate esters in the brain. Whereas several clinical trials have demonstrated the beneficial effects of sulbutiamine in patients with asthenia, there have been no reports on the effects of sulbutiamine on fatigue in patients with MS.


      Our study was designed to evaluate the short-term effects of sulbutiamine on fatigue in patients with MS.


      Patients were included if fatigue was one of their three predominant symptoms. They were required to have a total score on the Fatigue Impact Scale (FIS) of >20, and on the Beck Depression Inventory of <17, and no relapse in the last 3 months prior to onset of the study. Patients were advised to receive 400 mg orally of sulbutiamine once daily for two months. The outcome of the study was in the changes of FIS.


      Twenty-six patients with MS (18 females and 8 males) were selected. The patients were 18–57 years of age (mean:37,2). The average score of Expanded Disability Status Scale (EDSS) of the patients was 2,71. A significant number of the subjects who were on some kind of disease modifying treatment (DMT) demonstrated obvious improvement in their total FIS scores, whereas none of the subjects who were not on any DMT improved (13/23 vs. 0/5). The average fatigue score was 77 (SD:30,5) at the baseline and 60,5 (SD:29,7) on Day 60, respectively. Sulbutiamine intake resulted in a significant reduction on the total score of FIS and on all three subscales assessing physical, cognitive, and psychosocial functioning (all p-values < 0,01). There were no serious adverse events.


      Sulbutiamin appears to be effective in treating fatigue in MS; particularly in patients who were on some DMT, but not on those who were not. It is well-tolerated by all. This observation may encourage further evaluations of the efficacy of sulbutiamine on fatigue in MS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Armutlu K.
        • Keser İ.
        • Korkmaz N.
        • et al.
        Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients.
        J. Neurol. Sci. 2007; 15: 64-68
        • Branas P.
        • Jordan R.
        • Fry-Smith A.
        • et al.
        Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
        Health Technol. Assess. 2000; 4: 1-61
        • Bettendorff L.
        • Weekers L.
        • Wins P.
        • Schoffeniels E.
        Injection of sulbutiamine induces an increase in thiamine triphosphate in rat tissues.
        Biochem. Pharmacol. 1990; 40: 2557-2560
        • Bizot J.C.
        • Herpin A.
        • Pothion S.
        • et al.
        Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task.
        Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005; 29: 928-935
        • Calabrese M.
        • Rinaldi F.
        • Grossi P.
        • et al.
        Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis.
        Mult. Scler. 2010; 16: 1220-1228
        • Dobryakova E.
        • Genova H.M.
        • DeLuca J.
        • Wylie G.R.
        The dopamine imbalance hypothesis of fatigue in multiple sclerosis and other neurological disorders.
        Front. Neurol. 2015; 6: 52
        • Fisk J.D.
        • Pontefract A.
        • Ritvo P.G.
        • et al.
        The impact of fatigue on patients with multiple sclerosis.
        Can. J. Neurol. Sci. 1994; 21: 9-14
        • Finke C.
        • Schlichting J.
        • Papazoglou S.
        • et al.
        Altered basal ganglia functional connectivity in multiple sclerosis patients with fatigue.
        Mult. Scler. 2014; 21: 925-934
        • Flachenecker P.
        • Rufer A.
        • Bihler I.
        • et al.
        Fatigue in MS is related to sympathetic vasomotor dysfunction.
        Neurology. 2003; 61: 851-853
        • Fisk J.D.
        • Ritvo P.G.
        • Ross L.
        Measuring the impact of fatigue: Inıtial validation of the fatigue impact scale.
        Clin. Infect. Dis. J. Neurol. 1994; 18: 79-83
        • Gottschalk M.
        • Kümpfel T.
        • Flachenecker P.
        • et al.
        Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis.
        Arch. Neurol. 2006; 62: 277-280
        • Hadjimichael O.
        • Vollmer T.
        • Oleen-Burkey M.
        • et al.
        Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey.
        Health Qual. Life Outcomes. 2008; 6: 100-105
        • Induruwa I.
        • Constantinescu C.S.
        • Gran B.
        Fatigue in multiple sclerosis—A brief review.
        J. Neurol. Sci. 2012; 323: 9-15
        • Jongen P.J.
        • Lehnick D.
        • Koeman J.
        • et al.
        Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.
        J. Neurol. 2014; 261: 1469-1476
        • Krupp L.B.
        • Alvarez L.A.
        • LaRocca N.G.
        • Scheinberg L.C.
        Fatigue in multiple sclerosis.
        Arch. Neurol. 1998; 45: 435-437
        • Kapçı E.G.
        • Uslu R.
        • Türkçapar
        • et al.
        Beck Depression Inventory II: evaluation of the psychometric properties and cut-off points in a Turkish adult population.
        Depress Anxiety. 2008; 25: 104-110
        • Kwag J.
        • Majid A.S.
        • Kang K.D.
        Evidence for neuroprotective effect of sulbutiamine against oxygen-glucose deprivation in rat hippocampal CA1 pyramidal neurons.
        Biol. Pharm. Bull. 2011; 34: 1759-1764
        • Layzer R.B.
        Asthenia and the chronic fatigue syndrome.
        Muscle Nerve. 1998; 21: 1609-1611
        • Metz L.M.
        • Patten S.B.
        • Archibald C.J.
        • et al.
        The effect of immunomodulatory treatment on multiple sclerosis fatigue.
        J. Neurol. Neurosurg. Psychiatry. 2004; 75: 1045-1047
        • Nourbakhsh B.
        • Azevedo C.
        • Nunan-Saah J.
        • et al.
        Longitudinal associations between brain structural changes and fatigue in early MS.
        Mult. Scler. Relat. Disord. 2015; 5: 29-33
        • Polman C.H.
        • Reingold S.C.
        • Banwell B.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69: 292-302
        • Sumowski J.F.
        • Leavitt V.M.
        Body temperature is elevated and linked to fatigue in relapsing-remitting multiple sclerosis, even without heat exposure.
        Arch. Phys. Med. Rehabil. 2014; 95: 1298-1302
        • Shah S.N.
        • Sulbutiamine study group
        Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia.
        J. Assoc. Phys. India. 2003; 51: 891-895
        • Tellez N.
        • Rio J.
        • Tintore M.
        • et al.
        Fatigue in multiple sclerosis persists over time: a longitudinal study.
        J. Neurol. 2006; 253: 1466-1470
        • Tur C.
        Fatigue management in multiple sclerosis.
        Curr. Treat. Options Neurol. 2016; 18: 1-12
        • Trovero F.
        • Gobbi M.
        • Weil-Fuggaza J.
        • et al.
        Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain.
        Neurosci. Lett. 2000; 292: 49-53
        • Vucic S.
        • Burke D.
        • Kiernan M.C.
        Fatigue in multiple sclerosis: mechanisms and management.
        Clin. Neurophysiol. 2010; 121: 809-817
        • Yamashita H.
        • Zhang Y.X.
        • Nakamura S.
        The effects of thiamin and its phosphate esters on dopamine release in the rat striatum.
        Neurosci. Lett. 1993; 158: 229-231